ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

カプマチニブ

Capmatinib

HCID 25145656
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
1029712-80-8
標準SMILES
CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F
InChIKey
LIOLIMKSCNQPLV-UHFFFAOYSA-N
分子式
C23H17FN6O
平均分子量
412.4 g/mol
単同位体質量
412.14478735

概要

Capmatinib is a member of the class of imidazotriazines that is imidazo[1,2-b][1,2,4]triazine substituted by 3-fluoro-4-(methylcarbamoyl)phenyl and quinolin-6-ylmethyl groups at positions 2 and 7, respectively. It is a c-Met receptor tyrosine kinase inhibitor used for the treatment of non-small cell lung cancer with MET exon 14 skipping mutation. It has a role as an antineoplastic agent, a hepatotoxic agent, an apoptosis inducer and a c-Met tyrosine kinase inhibitor. It is a secondary carboxamide, a member of benzamides, a member of quinolines, an imidazotriazine and a member of monofluorobenzenes.

名称と識別子

優先名称
Capmatinib
IUPAC
2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
現地名
カプマチニブ
英語名
Capmatinib
分子式
C23H17FN6O
分子量
412.42

名称と別名

capmatinib1029712-80-8INCB28060INC-2802-fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamideINCB-28060NVP-INC280-NXINCB 28060NVP-INC280TY34L4F9OZ2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamideINCB-28060 FREE BASE
名称をさらに表示
カプマチニブ2-フルオロ-N-メチル-4-[7-[(6-キノリニル)メチル]イミダゾ[1,2-b][1,2,4]トリアジン-2-イル]ベンズアミドN-メチル-2-フルオロ-4-[7-(6-キノリルメチル)イミダゾ[1,2-b][1,2,4]トリアジン-2-イル]ベンズアミド2-フルオロ-N-メチル-4-{3-[(キノリン-6-イル)メチル]イミダゾ[1,2-b][1,2,4]トリアジン-6-イル}ベンズアミドN-メチル-4-[3-(6-キノリルメチル)イミダゾ[1,2-b][1,2,4]トリアジン-6-イル]-2-フルオロベンズアミド2-フルオロ-N-メチル-4-{7-[(キノリン-6-イル)メチル]イミダゾ[1,2-b][1,2,4]トリアジン-2-イル}ベンズアミドN-メチル-4-[7-(キノリン-6-イルメチル)-イミダゾ[1,2-b][1,2,4]トリアジン-2-イル]-2-フルオロベンズアミドINC280INC280602-Fluoro-N-Methyl-4-(7-quinolin-6-ylMethyl-iMidazo[1,2-b][1,2,4] triazin-2-yl)-benzaMideNC280CS-192Karma for,
DTXSID901455952-fluoro-N-methyl-4-{7-[(quinolin-6-yl)methyl]imidazo[1,2-b][1,2,4]triazin-2-yl}benzamide2-fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo(1,2-b)(1,2,4)triazin-2-yl)benzamidecapmatinibum2-fluoro-N-methyl-4-(7-((quinolin-6-yl)methyl)imidazo(1,2-b)(1,2,4)triazin-2-yl)benzamideRefChem:57919DTXCID4068086INCB028060

物性

構造計算による物性補完中

XLogP
2.9
極性表面積
85.1 Ų
水素結合供与体数
1
水素結合受容体数
6
回転可能結合数
4
重原子数
31
形式電荷
0
複雑度
637

実験および物理化学的性質

DrugsPharmaceuticals -> Listed in ZINC15
Human Drugs · 2 件

Breast Feeding; Lactation; Milk, Human; Enzyme Inhibitors; Protein Kinase Inhibitors; Signal Transduction Inhibitors

EMA approved medicines: Human medicine

物理化学的性質

融点
250 °C · >250°C (dec.)
比重(密度)
1.4 · 1.40
蒸気圧
0 · 0-0Pa at 20-25℃
貯蔵温度
-20 °C · -20°C Freezer, Under inert atmosphere
溶解性
DMSO(微量)、メタノール(微量)
酸解離定数(Pka)
13.82 · 13.82±0.46(Predicted)
外見
個体
色
淡黄色~淡黄色
InChI
InChI=1S/C23H17FN6O/c1-25-22(31)18-6-5-16(11-19(18)24)21-13-28-23-27-12-17(30(23)29-21)10-14-4-7-20-15(9-14)3-2-8-26-20/h2-9,11-13H,10H2,1H3,(H,25,31)
InChIKey
LIOLIMKSCNQPLV-UHFFFAOYSA-N
SMILES
C(NC)(=O)C1=CC=C(C2=NN3C(CC4=CC=C5C(=C4)C=CC=N5)=CN=C3N=C2)C=C1F
LogP

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Danger

H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]

P203, P260, P264, P270, P273, P280, P301+P316, P318, P319, P321, P330, P391, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 8 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Regulatory InformationREACH registered substance: 2-Fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide (EC: 813-241-9)
Hazard Classes and CategoriesAcute Tox. 3 (100%)

毒性情報

Hepatotoxicity · 1 件

In the prelicensure clinical trials of capmatinib in patients with solid tumors harboring MET mutations, liver test abnormalities were frequent although usually self-limited and mild. Some degree of ALT elevations arose in 39% of capmatinib treated patients and were above 5 times the upper limit of normal (ULN) in 7%. In these trials that enrolled 373 patients, capmatinib was discontinued early due to increased AST or ALT in only 1% of patients. The liver test abnormalities had a median onset of 2 months after initiation of therapy. While serum aminotransferase elevations were occasionally quite high (5 to 20 times upper limit of normal), there were no accompanying elevations in serum bilirubin and no patient developed clinically apparent liver injury with jaundice. The product label for capmatinib recommends monitoring for routine liver tests before, at 2-week intervals during the first 3 months of therapy, and monthly thereafter as clinically indicated. However, since its approval and more wide-spread clinical use, there have been several reports of acute liver injury with jaundice in patients receiving capmatinib. The onset is after 6 to 8 weeks, and the clinical pattern is hepatocellular with features resembling severe acute viral hepatitis. Immune allergic and autoimmune features are not common, and recovery occurs typically within 2 to 3 months, but at least one fatal incident has been reported. Strikingly, most cases have occurred shortly after previous chemotherapy with a checkpoint inhibitor (within 2 to 4 months of the last dose). A similar frequent occurrence of liver injury following recent use of checkpoint inhibitors has been reported with other kinase inhibitors (sotorasib, crizotinib, osimertinib). These findings suggest that capmatinib not be started within 4 months of the last dose of a checkpoint inhibitor.

化学と産業

薬理情報

ATC Code · 2 件

L - Antineoplastic and immunomodulating agents

QL - Antineoplastic and immunomodulating agents

Protein BindingPlasma protein binding is approximately 96% and is independent of drug serum concentration.
Pharmacodynamics · 1 件

Capmatinib inhibits the overactivity of c-Met, a receptor tyrosine kinase encoded by the _MET_ proto-oncogene. Mutations in _MET_ are involved in the proliferation of many cancers, including non-small cell lung cancer (NSCLC). Capmatinib may cause photosensitivity reactions in patients following ultraviolet (UV) exposure - patients undergoing therapy with capmatinib should be advised to use sunscreen and protective clothing to limit exposure to UV radiation. Instances of interstitial lung disease/pneumonitis, which can be fatal, occurred in patients being treated with capmatinib. Patients presenting with signs or symptoms of lung disease (e.g. cough, dyspnea, fever) should have capmatinib immediately withheld, and capmatinib should be permanently discontinued if no other feasible causes of the lung-related symptoms are identified.

Mechanism of Action · 1 件

Aberrant activation of c-Met has been documented in many cancers, including non-small cell lung cancer (NSCLC). Mutations that result in the skipping of _MET_ exon 14 lead to the formation of a mutant c-Met with a missing regulatory domain - these mutant proteins have a reduced ability to negatively regulate, leading to a pathological increase in their downstream activity. Capmatinib inhibits the phosphorylation of both wild-type and mutant variants of c-Met triggered by the binding of its endogenous ligand, hepatocyte growth factor - in doing so, it prevents c-Met-mediated phosphorylation of downstream signaling proteins, as well as the proliferation and survival of c-Met-dependent tumor cells.

Biological Half-LifeThe elimination half-life is 6.5 hours.
Metabolism/MetabolitesCapmatinib undergoes metabolism primarily via CYP3A4 and aldehyde oxidase. Specific biotransformation pathways and metabolic products have yet to be elucidated.

関連反応

11 件
反応記録を作成
HRID 947337 の反応式
HRID 947337生成物として
HRID 1396516 の反応式
HRID 1396516反応物として
HRID 1396531 の反応式
HRID 1396531生成物として
HRID 1396532 の反応式
HRID 1396532反応物として
HRID 1396537 の反応式
HRID 1396537生成物として
HRID 1396538 の反応式
HRID 1396538生成物として
HRID 1966357 の反応式
HRID 1966357反応物として
HRID 1966372 の反応式
HRID 1966372生成物として
前へ1 / 2 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
1029712-80-8
PubChem CID
25145656
DTXSID
DTXSID90145595
ChEMBL
CHEMBL3188267
ChEBI
CHEBI:231693
UNII
TY34L4F9OZ
EC Number
813-241-9
Nikkaji
J3.320.942H
1.6 · 1.6-2.2 at 35℃ and pH7-9
Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

安全データ

注意喚起語
警告
危険有害性情報
コード 危険有害性情報 危険有害性クラス 区分 注意喚起語 シンボル P コード H302
FDA Pharmacological Classification · 6 件

TY34L4F9OZ

CAPMATINIB

Established Pharmacologic Class [EPC] - Kinase Inhibitor

Mechanisms of Action [MoA] - Mesenchymal Epithelial Transition Inhibitors

Mechanisms of Action [MoA] - Cytochrome P450 1A2 Inhibitors

Mechanisms of Action [MoA] - P-Glycoprotein Inhibitors

Absorption, Distribution and Excretion · 4 件

The oral bioavailability of capmatinib is estimated to be >70%. Following oral administration, maximum plasma concentrations are achieved within 1 to 2 hours (Tmax). Co-administration with a high-fat meal increased capmatinib AUC by 46% with no change in Cmax (as compared to fasted conditions), and co-administration with a low-fat meal had no clinically meaningful effects on exposure.

Following oral administration of radiolabeled capmatinib, approximately 78% of the radioactivity is recovered in feces, of which ~42% is unchanged parent drug, and 22% is recovered in the urine, of which a negligible amount remains unchanged parent drug.

The apparent volume of distribution at steady-state is 164 L.

The mean apparent clearance of capmatinib at steady-state is 24 L/h.

応用分野 · 2 件

説明Capmatinib is a competitive inhibitor with very potent and selective activity against MET compared to other kinases.

使用2-Fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide is used in the preparation of a combination formulation with allosteric SHP2 inhibitor TNO155. Used in treatment of non-small cell lung cancer with specific mutations (those that lead to mesenchymal-epithelial transition or MET exon 14 skipping).

上流・下流製品情報

上流原料

Benzamide, 2-fluoro-4-[7-(6-quinolinylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]-メチルアミントリエチルアミン2-fluoro-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzoicacidN,N-ジメチルホルムアミドテトラヒドロフランジメチル硫酸